Every story stays here. Filter by topic, search older headlines, and save favorites to your member record. Educational notes only — not medical advice.
Study (randomized trial). LatAm-FINGERS, presented at AAIC 2026 and published in The Lancet, followed 1,065 older adults at 12 sites in 11 Latin American countries for two years. A structured program (coached exercise including salsa and tango, a locally adapted MIND diet, cognitive training, vascular-risk checks, and 38 group meetings) produced a 55% greater gain on a global cognition composite than a lighter education arm. Memory, executive function, and processing speed also improved more with coaching. This is risk-reduction research, not a dementia cure and not a supplement protocol.
Study (observational plus Mendelian randomization). Zhao, Sun, Zhang and Ye (Hong Kong and Georgia) analyzed more than 270,000 UK Biobank participants in Aging-US. Higher blood tyrosine tracked with shorter predicted male lifespan—about a year in genetic estimates—while women showed no significant effect. Phenylalanine dropped out after adjusting for tyrosine. The authors did not test tyrosine pills; this is not proof that a focus supplement shortens life. Protein restriction to lower tyrosine is unproven as a longevity tactic and can work against muscle in older adults. Discuss supplements with a clinician.
Commentary covering a study. Yale researchers (Sehgal, Higgins-Chen and colleagues) pooled 51 human intervention studies in Nature Medicine and ran the same panel of 16 epigenetic clocks plus 94 other DNA-methylation markers. Diet patterns (Mediterranean, low-carb, or low-fat) plus regular exercise consistently lowered clock estimates. Prescription metformin, semaglutide, and anti-TNF therapies showed the largest average clock drops, often in people already treated for disease. Over-the-counter supplements were limited and inconsistent. Authors stress that a biomarker shift is not proof of extra healthy years. Metformin and GLP-1 drugs remain prescription medicines; off-label longevity use is clinician-only. This is not medical advice. Educational supplement parallel (not a replacement): When longevity headlines discuss metformin, people often also research berberine. That is an off-label / curiosity parallel, not a recommendation to take berberine instead of metformin. Human longevity outcome data for both are limited; disease-use of metformin is clinician-prescribed. Weakly evidenced as an anti-aging product. Store: /store/berberine. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline. Educational supplement parallel (not a replacement): When headlines discuss GLP-1 medicines and aging, people often research food-first fiber or bitter-botanical “pathway support” formulas. Those are not semaglutide, not compounded GLP-1, and not a substitute for a prescribed GLP-1 drug. Mouse or marketing claims are hype until human outcome data exist. Weakly evidenced. Store: /store/glp1-pathway-support. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
Commentary. A Medical Xpress science roundup (Sept. 4, 2026) argues that ice baths, compression, massage, and recovery supplements often trim soreness a little without restoring muscle function much. Stronger evidence sits with basics: 7–9 hours of sleep, 20–40 g protein after training plus carbohydrate to refill glycogen, and a plan with rest days. Omega-3 pills are unlikely to vastly improve recovery versus food. This is educational training hygiene, not a supplement protocol and not a diagnosis.
Study (mice). Salk Institute researchers led by Gerald Shadel report in Science Advances that brief mitochondrial stress during mouse embryonic development later protected adult hearts from doxorubicin, a chemotherapy drug that can damage mitochondria. Superoxide buildup led mitochondria to release citrate, which converted to acetyl-CoA and left lasting epigenetic “mitohormesis” marks. This is laboratory animal work, not a human longevity trial and not a reason to take antioxidant pills or skip prescribed heart or cancer care. Mitohormesis as an anti-aging product is weakly evidenced.
Study (observational). INRAE’s Bernard Srour and colleagues analysed 104,806 adult NutriNet-Santé participants (2009–2023) and report in Communications Medicine that weekday–weekend meal-timing shifts (“eating jetlag”) tracked with cardiovascular disease in men: each extra hour of advance or delay was associated with about 14% higher CVD risk and 21% higher coronary risk after sleep, diet, and lifestyle adjustment. No significant association was seen in women. Advance averaged about 2 hours earlier on weekends; delay about 1 hour 40 minutes later. Observational, not proof that regular mealtimes prevent heart disease. Educational timing notes, not medical advice.
Study (genetic). NYU Langone Health researchers led by Lynn Petukhova report in the Journal of Investigative Dermatology that genetically higher GLP-1 receptor (GLP1R) activity is linked to about 7% added risk of male-pattern androgenetic alopecia, remaining after adjustment for hypertension, insulin resistance, and testosterone-related factors. Databases included eQTLGen (31,684 people) and a male complex-traits set (205,327). The analysis could not yet test women the same way. This is not a reason to start, stop, or replace a prescribed GLP-1 drug. Off-label longevity use is clinician-only. Not medical advice. Educational supplement parallel (not a replacement): When headlines discuss GLP-1 medicines and aging, people often research food-first fiber or bitter-botanical “pathway support” formulas. Those are not semaglutide, not compounded GLP-1, and not a substitute for a prescribed GLP-1 drug. Mouse or marketing claims are hype until human outcome data exist. Weakly evidenced. Store: /store/glp1-pathway-support. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
Commentary (review). A Hamad Bin Khalifa University review in Aging (DOI 10.18632/aging.206407) gathers cell, animal, and human studies on metformin and biological aging. The authors describe AMPK activation, autophagy, DNA-methylation stability, and microbiome shifts. Animal data include longer C. elegans lifespan and mixed mouse lifespan gains; human signals are mostly observational in people with diabetes, and a widely cited survival paper has been hard to reproduce. The planned TAME trial is meant to test whether metformin delays age-related disease in people without diabetes. Metformin remains a prescription medicine for type 2 diabetes. Off-label longevity use is clinician-only. This is not medical advice and not a reason to start, stop, or replace any drug. Educational supplement parallel (not a replacement): When longevity headlines discuss metformin, people often also research berberine. That is an off-label / curiosity parallel, not a recommendation to take berberine instead of metformin. Human longevity outcome data for both are limited; disease-use of metformin is clinician-prescribed. Weakly evidenced as an anti-aging product. Store: /store/berberine. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
Study (mice and human cells). Stanford Medicine researchers report in Science that tissue-resident macrophages lose the ability to clear senescent neutrophils with age. Blocking the PGE2 receptor EP2 on those macrophages in mice restored cleanup and left older animals leaner, stronger, and sharper across brain, heart, muscle, liver, and other organs. Human liver-cell data showed similar neutrophil buildup and EP2 activity with age. This is laboratory and observational tissue work, not a clinic protocol. No approved EP2-selective drug exists; NSAIDs that broadly lower prostaglandins are not a longevity prescription.
Commentary. Meeting report from the SENESCENCE2030 conference in Coimbra (May 2026). Researchers sketched priorities: classifying senescent cell states, standardizing biomarkers, and coordinating translation. Educational context for how the field talks about cellular aging — not a clinic visit and not a supplement protocol.
Commentary. A Nature Aging research highlight on mouse work in which GLP-1 receptor agonism was associated with a longer median lifespan. This is laboratory animal research, not a human trial and not a reason to start, stop, or change any medicine. VitaLonga does not prescribe GLP-1 drugs or sell them as longevity treatments. Educational supplement parallel (not a replacement): When headlines discuss GLP-1 medicines and aging, people often research food-first fiber or bitter-botanical “pathway support” formulas. Those are not semaglutide, not compounded GLP-1, and not a substitute for a prescribed GLP-1 drug. Mouse or marketing claims are hype until human outcome data exist. Weakly evidenced. Store: /store/glp1-pathway-support. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
Study (observational). Shieh, Karlamangla and colleagues, using 964 women in the SWAN Bone Cohort with a known final menstrual period (mean age about 49 at first visit), report in the Journal of Clinical Investigation that circulating markers of gut-barrier strain (FABP2 and sCD14) rose across about nine years around menopause. FABP2 began climbing about 2.5 years before the final period and slowed about 6.5 years after; sCD14 lagged by about six months. This is indirect blood-marker work, not a leaky-gut diagnosis or a probiotic trial. Educational menopause-aging notes, not medical advice.
VitaLonga is an educational longevity resource, not a pharmacy, clinic, or doctor. Content is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease (DSHEA). Supplements can interact with medications and are not appropriate in every pregnancy or health condition. Consult a licensed clinician, especially if you take medications, are pregnant or nursing, or have a diagnosed condition.
